| Name | Title | Contact Details |
|---|---|---|
Misty Greficz |
Director of Marketing | Profile |
Michael Balsam |
Chief Product Officer | Profile |
Mo Harrim |
VP Product | Profile |
Dwight Scott |
Senior Director of Human Resources | Profile |
iCarbonX is building a digital life ecosystem by combining consumer life data, the Internet and artificial intelligence.
Agility Therapy is a Grand Rapids, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Advion BioSciences, Inc. was founded in 1993 based on the novel techniques developed within the Cornell University laboratory of Dr. Jack Henion, a leading researcher in the field of Liquid Chromatography/Mass Spectrometry (LC/MS).
Alector is combining state-of-the-art antibody technology and recent discoveries in neuroimmunology and human genetics to develop novel therapeutics for Alzheimer`s disease, other forms of dementia, and mechanistically related neurodegenerative disorders. Alector`s strategy is to efficiently generate and validate antibody drugs with unique functional properties that engage key disease-altering targets. This approach is enabled by a strategic alliance with Adimab, the industry leader in discovery and optimization of antibody therapeutics. Alector is currently developing leads for 4 major targets and anticipates taking 2 of these through pre-clinical development and IND enabling studies within 24 months. Alector has incorporated a highly integrated and lean biotechnology structure with extensive outsourcing that supports core scientific and management teams.
Portola Pharmaceuticals is dedicated to developing and commercializing therapies that transform patient lives and advance patient care by changing treatment paradigms in thrombosis and other hematologic diseases. Our two lead assets are Bevyxxa® (betrixaban), and andexanet alfa. In addition, cerdulatinib is our investigational Syk/JAK inhibitor to treat hematologic cancers. These compounds come from our own internal research efforts and represent important advances to address significant unmet needs. We are employing novel strategies that may increase the likelihood of clinical, regulatory and commercial success of our potentially lifesaving therapies.